Purchase this article with an account.
David Cordeiro Sousa, Pablo Zoroquiain, Evangelina Esposito, Maria Eugenia Orellana, Bruna Duarte Moron de Andrade, Miguel N Burnier; HER2 expression in retinoblastoma: a potential therapeutic target?. Invest. Ophthalmol. Vis. Sci. 2017;58(8):1776.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
Retinoblastoma (RB) is the most common primary intraocular malignancy in children. Current therapies are associated with both high short- and long-term morbidity. Human epidermal growth factor receptor 2 (HER2) is a transmembrane protein detected in 15%–30% of breast cancers, which has also been described in other malignancies. Recently, it was reported that a truncated version of this protein is expressed in RB, which is responsive to targeted therapies in vitro. Herein, we scored HER2 expression in RB samples and discuss its potential clinical utility.
A total of 60 RB cases and the Y79 RB cell line were evaluated for HER2 expression using a monoclonal antibody and the fully automated Ventana immunostaining system. HER2 expression was evaluated using the traditional 0 to 3+ scoring method according to the membranous staining pattern in archival formalin-fixed, paraffin-embedded RBs. A cell block was generated with the Y79 cell line, and it was scored in a similar fashion.
The mean age at enucleation was 31.6 ± 31.5 months, while the mean time from diagnosis to enucleation was 11.8 ± 11.2 months (range 1–44 months). Five cases (8%) were multifocal. HER2 expression was negative in all RB cases (49 cases scored 0 and 11 scored 1+) and in the Y79 cell line.
Despite the large sample size, and the inclusion of a RB cell line, in our study, there was no significant expression of HER2 in RB. Based on our results, it is unlikely that anti-HER2 therapies will be effective for treating RB via the traditional pathways.
This is an abstract that was submitted for the 2017 ARVO Annual Meeting, held in Baltimore, MD, May 7-11, 2017.
This PDF is available to Subscribers Only